Search results
Results from the WOW.Com Content Network
On December 17, 2009, Rev. Bryan A. Krumm, CNP, filed a rescheduling petition for Cannabis with the DEA arguing that "because marijuana does not have the abuse potential for placement in Schedule I of the CSA, and because marijuana now has accepted medical use in 13 states, and because the DEA's own Administrative Law Judge has already ...
The first hearing to go over the Biden administration’s proposal to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act was set to begin Jan. 21.
Rescheduling marijuana as a Schedule III drug is a monumental moment in U.S. drug policy history. Cannabis has been listed as a Schedule I drug - with no medicinal value and a high potential for ...
By rescheduling cannabis, the drug would now be studied and researched to identify concrete medical benefits, opening the door for pharmaceutical companies to get involved with the sale and ...
“By rescheduling marijuana to schedule 3, the DEA would not only be breaking the law but also rejecting established science," Sabet said. "The DEA and the FDA have held long-standing opinions ...
Marijuana has been considered a Schedule I drug since the Controlled Substances Act was signed in 1970, ... "Rescheduling won't legalize cannabis or let a doctor prescribe it, but it will allow ...
The Drug Enforcement Administration initiated a 2024 policy review to potentially reschedule marijuana as a Schedule III drug, amounting to "the agency's biggest policy change in more than 50 years". [4] Some hiring and retention policies in federal employment and the armed forces evolved during 2024.
Health and Human Services recommended that DEA reschedule marijuana to Schedule III in 2023. For decades, cannabis has been classified as a Schedule I drug, a class defined as drugs with no ...